Related Experiment Video

Updated: Jan 2, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.6K

The Level of Circulating Microparticles in Patients with Coronary Heart Disease: a Systematic Review and

Baofu Wang1, Tong Li1, Xiaowan Han1

  • 1Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Beijing University of Chinese Medicine, Dongzhimen Hospital, Beijing, China.

Journal of Cardiovascular Translational Research
|December 14, 2019
PubMed

Insights

Microparticles (MPs) are significantly elevated in coronary heart disease (CHD) patients. Higher MP levels correlate with increased CHD severity, suggesting their potential as biomarkers for stable angina, unstable angina, and myocardial infarction.

Area of Science:

  • Cardiovascular Research
  • Biomarker Discovery
  • Translational Medicine

Background:

  • Coronary heart disease (CHD) encompasses conditions like stable angina (SA), unstable angina (UA), and myocardial infarction (MI).
  • Microparticles (MPs) are cell-derived vesicles implicated in various pathological processes, including cardiovascular disease.

Purpose of the Study:

  • To investigate the correlation between microparticle (MP) levels and different subgroups of coronary heart disease (CHD).
  • To evaluate MPs as potential diagnostic or prognostic biomarkers for SA, UA, and MI.

Main Methods:

  • Systematic literature search for case-control studies on MPs and CHD.
  • Meta-analysis of pooled standardized mean differences (SMDs) to compare MP levels between patient groups and healthy controls.
  • Subgroup analyses were performed for specific MP types, including CD31+CD42- endothelium-derived microparticles (EMPs) and CD144+EMPs.

Main Results:

  • Patients with CHD exhibited significantly higher MP levels compared to normal subjects (SMD 2.28).
  • MP levels were significantly elevated across CHD subgroups: UA vs SA (SMD 2.35), MI vs SA (SMD 3.08), and MI vs UA (SMD 0.83).
  • Specific EMP subgroups (CD31+CD42- and CD144+) showed similar trends, with levels increasing proportionally to CHD severity (Normal < SA < UA < MI).

Conclusions:

  • Microparticle levels, particularly CD31+CD42-EMPs and CD144+EMPs, demonstrate a clear increasing trend with the severity of coronary heart disease.
  • These findings suggest that microparticles hold significant potential as biomarkers for identifying and stratifying patients with SA, UA, and MI.
Abstract

Keywords:
Coronary heart diseaseMicroparticlesMyocardial infarctionStable anginaUnstable angina

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.7K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.3K

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
547
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
314
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
195
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
165
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
284
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
314